Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Aprepitant Injection(QLG2174) in the Prevention of Post-operative Nausea and Vomiting
NCT06932107 is registered in ClinicalTrials.gov with Qilu Pharmaceutical (Hainan) Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Aprepitant Injection(QLG2174) in the Prevention of Post-operative Nausea and Vomiting
- Lead sponsor
- Qilu Pharmaceutical (Hainan) Co., Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- February 2, 2024
- Completion date
- June 5, 2024
- Enrollment
- 518 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.